Alembic Pharmaceuticals Limited (BOM:533573)
768.55
+6.80 (0.89%)
At close: Jan 22, 2026
Alembic Pharmaceuticals Revenue
Alembic Pharmaceuticals had revenue of 19.10B INR in the quarter ending September 30, 2025, with 15.91% growth. This brings the company's revenue in the last twelve months to 70.83B, up 11.42% year-over-year. In the fiscal year ending March 31, 2025, Alembic Pharmaceuticals had annual revenue of 66.72B with 7.12% growth.
Revenue (ttm)
70.83B
Revenue Growth
+11.42%
P/S Ratio
2.14
Revenue / Employee
4.27M
Employees
16,571
Market Cap
151.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 66.72B | 4.43B | 7.12% |
| Mar 31, 2024 | 62.29B | 5.76B | 10.19% |
| Mar 31, 2023 | 56.53B | 3.47B | 6.54% |
| Mar 31, 2022 | 53.06B | -873.40M | -1.62% |
| Mar 31, 2021 | 53.93B | 7.87B | 17.10% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 76.18B |
| Granules India | 48.42B |
| J. B. Chemicals & Pharmaceuticals | 41.93B |
| FDC Limited | 20.77B |
| Caplin Point Laboratories | 20.42B |
| AstraZeneca Pharma India | 20.06B |
| Sanofi India | 19.33B |
| Viyash Scientific | 16.58B |
Alembic Pharmaceuticals News
- 4 days ago - Pharma sector stocks fall today: Cipla drops 1.52%, Divi’s Laboratories falls 0.78%, Alembic Pharma down 0.52% - Business Upturn
- 7 days ago - Pharma sector stocks today: Sun Pharma falls 1.43%, Ipca Labs down 1.32%, Alembic Pharma drops 1.08% - Business Upturn
- 11 days ago - Alembic Pharmaceuticals secures USFDA tentative approval for Bosutinib 400 mg tablets - Business Upturn
- 5 weeks ago - Alembic Pharma gets USFDA final approval for Travoprost Ophthalmic Solution - Business Upturn
- 6 weeks ago - Alembic Pharmaceuticals secures USFDA approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3% - Business Upturn
- 2 months ago - Alembic Pharma shares rise over 2% after USFDA nod for Diltiazem Hydrochloride Tablets - Business Upturn
- 2 months ago - Alembic Pharma gets USFDA final nod for Diltiazem Hydrochloride Tablets - Business Upturn
- 2 months ago - Alembic Pharma secures final USFDA approval for Dexlansoprazole DR capsules - Business Upturn